Genomic test cuts brain tumor diagnosis from 8 weeks to 2 hours
NHS pilots rapid intraoperative testing in five UK centers, enabling earlier treatment decisions.
1Diagnostic breakthrough
A new genomic test developed by the University of Nottingham's Brain Tumour Research Centre can identify tumor types within two hours during surgery, compared to the traditional eight-week wait. The NHS is piloting this technology in five specialist centers, potentially transforming treatment pathways for aggressive brain tumors that disproportionately affect young people.
2Surgical decision advantage
The test provides neurosurgeons with detailed genetic tumor profiles while patients are still on the operating table. This real-time data allows immediate adjustments to surgical strategy and eligibility assessment for clinical trials. Consultant neurosurgeon Stuart Smith emphasizes this eliminates the critical waiting period where patients often deteriorate.
3Nanopore sequencing tech
The portable Oxford Nanopore device analyzes tumor DNA by passing molecules through microscopic pores. This shoebox-sized lab equipment generates comprehensive genomic data faster than traditional pathology methods. The technology's speed comes from bypassing complex sample preparation required for conventional sequencing.
4Clinical impact
Early results show the test could significantly improve outcomes for patients with aggressive gliomas who typically face diagnostic delays. NHS England's medical director highlights its potential to change standard care protocols. The approach may particularly benefit pediatric cases where rapid treatment initiation is crucial.
5Implementation roadmap
Initial rollout focuses on five leading neurosurgical centers: Nottingham, Birmingham, Great Ormond Street, King's College, and Newcastle. Subsequent expansion will include Bristol, Oxford, Leeds and Manchester. This phased approach allows protocol refinement before nationwide adoption.
6Epidemiological context
Brain tumors remain the leading cause of cancer death for UK adults under 40. Current diagnostic bottlenecks force patients to wait weeks for pathology results while tumors progress. The new test directly addresses this critical gap in neuro-oncology care pathways.
7Operational workflow
During surgery, small tumor samples are immediately sent to adjacent pathology labs for sequencing. The streamlined process eliminates multiple handling steps in traditional histopathology. This integration of molecular diagnostics into surgical workflow represents a paradigm shift in neuro-oncology.
8Future implications
Success could establish a new standard for intraoperative molecular diagnostics across cancer types. The NHS's adoption signals confidence in genomic medicine's role in acute care. Researchers anticipate similar approaches may soon emerge for other time-sensitive malignancies.